NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
VarmX Appoints Dr. Jeffrey Lawson, MD, PhD as Chief Scientific Officer<
09 Mar 2023

VarmX Appoints Dr. Jeffrey Lawson, MD, PhD as Chief Scientific Officer

Dr. Lawson is a renowned scientist in blood coagulation biochemisty and surgical hemostasis.
Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC<
04 Mar 2023

Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC

Lorundrostat demonstrated clinically meaningful blood pressure reduction in individuals with uncontrolled hypertension
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update<
03 Mar 2023

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Closed $31.0 million private placement financing, extending cash runway into 1Q 2025

AELIX Therapeutics presents positive results from randomized placebocontrolled phase IIa therapeutic HIV vaccine and immune modulator combination clinical trial<
22 Feb 2023

AELIX Therapeutics presents positive results from randomized placebocontrolled phase IIa therapeutic HIV vaccine and immune modulator combination clinical trial

The study achieved its primary and secondary endpoints of safety, tolerability and immunogenicity.
Xeltis raises €32 million to drive clinical development of world’s most advanced restorative cardiovascular devices<
21 Feb 2023

Xeltis raises €32 million to drive clinical development of world’s most advanced restorative cardiovascular devices

Use of proceeds to advance Xeltis’ aXess vascular access graft into pivotal clinical trials
Lava Therapeutics announces initial data from the ongoing phase 1/2a clinical trial of LAVA-1207 in therapy refractory MCRPC at the 2023 ASCO GU symposium<
16 Feb 2023

Lava Therapeutics announces initial data from the ongoing phase 1/2a clinical trial of LAVA-1207 in therapy refractory MCRPC at the 2023 ASCO GU symposium

Favorable safety profile to date, with no occurrence of high-grade (>2) cytokine release syndrome or dose-limiting toxicities
Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administrationat the Macula Society 46th Annual Meeting<
16 Feb 2023

Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administrationat the Macula Society 46th Annual Meeting

These latest results strongly support the potential of bel-sar to be used as a first line treatment option for patients with early-stage choroidal melanoma
Mineralys Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares<
15 Feb 2023

Mineralys Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

The aggregate gross proceeds from the offering were $220.8 million, before deducting underwriting discounts and commissions and other offering expenses
Mineralys Therapeutics Announces Pricing of Upsized Initial Public Offering<
14 Feb 2023

Mineralys Therapeutics Announces Pricing of Upsized Initial Public Offering

The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $192.0 million
Lava Therapeutics announces the appointment of Dr. Charles Morris as Chief Medical Officer<
06 Feb 2023

Lava Therapeutics announces the appointment of Dr. Charles Morris as Chief Medical Officer

Dr. Morris is a medical oncologist with over 25 years of oncology drug development experience

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка